文献速递慢阻肺

慢阻肺精准医学导论

Introduction to precision medicine in COPD.
PubMed 文献 · Eur Respir J · 2019-04-11

本文讨论精准医学概念及其在慢阻肺中的应用。慢阻肺具有多表型和内型异质性,需从一刀切模式转向考虑基因、环境和生活方式个体差异的精准医学。生物标志物可用于识别治疗获益亚组、预测个体药物反应及区分预后风险。

要点

  • 慢阻肺是异质性疾病,需从一刀切转向精准医学。
  • 预测性生物标志物识别治疗获益或仅受害亚组。
  • 反应性标志物预测个体药物反应,预后标志物区分风险。

核心结论

  • 慢阻肺需从一刀切模式转向精准医学,考虑基因、环境和生活方式个体差异。

研究设计与样本

  • 本文为导论性文章,讨论精准医学概念及其在慢阻肺中的相关性。

主要发现

  • 慢阻肺被广泛接受为具有多表型和内型的异质性疾病。
  • 精准医学由生物标志物实现,包括预测性、反应性和预后性生物标志物。

关键数值与推荐

  • 预测性生物标志物准确识别最可能从治疗获益或仅受害的患者亚组。
  • 反应性生物标志物预测个体水平药物反应。
  • 预后性生物标志物区分预后不良风险患者与相对稳定患者。

临床怎么用

  • 探索为全球数百万慢阻肺患者实施精准医学的途径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although there has been tremendous growth in our understanding of chronic obstructive pulmonary disease (COPD) and its pathophysiology over the past few decades, the pace of therapeutic innovation has been extremely slow. COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. Thus, there is a pressing need for COPD care to move from the current "one-size-fits-all" approach to a precision medicine approach that takes into account individual patient variability in genes, environment and lifestyle. Precision medicine is enabled by biomarkers that can: 1) accurately identify subgroups of patients who are most likely to benefit from therapeutics and those who will only experience harm (predictive biomarkers); 2) predict therapeutic responses to drugs at an individual level (response biomarkers); and 3) segregate patients who are at risk of poor outcomes from those who have relatively stable disease (prognostic biomarkers). In this essay, we will discuss the current concept of precision medicine and its relevance for COPD and explore ways to implement precision medicine for millions of patients across the world with COPD.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Leung JM, Obeidat M, Sadatsafavi M, et al. Introduction to precision medicine in COPD. Eur Respir J. 2019. PMID: 30679189. doi:10.1183/13993003.02460-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。